Neuland Laboratories Limited.
₹19,701.10+₹425.15 (+2.2%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹18,376 Cr
- P/E
- 94.3x
- EV / EBITDA
- 38.6x
- Revenue
- ₹1,477 Cr
- Net margin
- 19.2%
- ROCE
- 33.7%
Price chart
Technical chartScreen technicals →+21.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -7.9%
- 3M
- +2.5%
- 6M
- +31.4%
- 1Y
- +21.8%
- 5Y
- +1,066.5%
52-week range
Day change +₹425.15 (+2.2%) from ₹19,276 to ₹19,701 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in NEULANDLAB, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 15.4%
Concerns0
Rule-based from financial data. Not advice.
About the company
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 1.3 Cr shares
- ISIN
- INE794A01010
- BSE code
- 524558
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹18,376 Cr
- P/E
- 94.3x
- P/B
- 11.4x
- EV / EBITDA
- 38.6x
- EV / Sales
- 11.7x
- P/S
- 11.8x
- Earnings yield
- 1.1%
- 52-week high
- ₹23,973.70
- 52-week low
- ₹11,549.75
Profitability
- Operating margin
- 29.6%
- Net margin
- 19.2%
- EBITDA margin
- 30.4%
- ROE
- 23.5%
- ROCE
- 33.7%
- ROA
- 16.4%
- Dividend payout
- 6.0%
- Tax rate
- 25.0%
- Other income, % of PBT
- 3.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,477 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -5.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.4%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹474 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 68.7%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -13.7%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 79.7%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹260 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹44.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 16.0%
Solvency and efficiency
- Current ratio
- 2.09
- Debt / Equity
- 0.07
- Debt / Assets
- 0.05
- Debt / EBITDA
- 0.20
- Interest coverage
- 33.00
- Financial leverage
- 1.43
- CFO / Net profit
- 0.87
- Cash / Market cap
- 5.2%
- Cash per share
- ₹748.42
- Asset turnover
- 0.85
- Fixed asset turnover
- 1.89
- Capital intensity
- 0.53
- Debtor days
- 87 days
- Inventory turnover
- 1.66
- Cash conversion cycle
- 183 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹18 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,147 Cr |
| Sales | Operating profit | ₹330 Cr |
| Operating profit | Interest | ₹8 Cr |
| Operating profit | Depreciation | ₹66 Cr |
| Operating profit | Profit before tax | ₹256 Cr |
| Other income | Profit before tax | ₹90 Cr |
| Profit before tax | Tax and other | ₹86 Cr |
| Profit before tax | Net profit | ₹259 Cr |
Revenue and net profit
Revenue fell 5.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹937 Cr | ₹80 Cr |
| FY2022 | ₹951 Cr | ₹64 Cr |
| FY2023 | ₹1,191 Cr | ₹163 Cr |
| FY2024 | ₹1,559 Cr | ₹300 Cr |
| FY2025 | ₹1,477 Cr | ₹259 Cr |
Cash flows
FY2025: ₹317 Cr from operations, ₹19.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹189 Cr | ₹105 Cr |
| FY2022 | ₹60 Cr | -₹36 Cr |
| FY2023 | ₹239 Cr | ₹177 Cr |
| FY2024 | ₹260 Cr | ₹110 Cr |
| FY2025 | ₹317 Cr | ₹19 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,477 Cr-5.3%1Y
- Net profit
- ₹259 Cr-13.7%1Y
- Cash from operations
- ₹317 Cr
- Free cash flow
- ₹19 Cr-82.7%1Y
- Revenue CAGR, 5Y
- 15.4%
- EBITDA CAGR, 5Y
- 35.2%
- Net profit CAGR, 5Y
- 79.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,477 Cr | ₹330 Cr | — | ₹259 Cr | ₹317 Cr | ₹19 Cr | 17.1% | -5.3% | -13.7% |
Monthly returns
Month-by-month returns of NEULANDLAB across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,178 Cr |
| Equity capital | ₹13 Cr |
| Reserves | ₹1,505 Cr |
| Borrowings | ₹157 Cr |
| Other liabilities | ₹503 Cr |
| Assets | ₹2,178 Cr |
| Fixed assets | ₹955 Cr |
| Capital work in progress | ₹48 Cr |
| Investments | ₹109 Cr |
| Other assets | ₹1,066 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
NEULANDLAB trades at 94.3x earnings against a peer median of 52.6x (a 79% premium).
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Neuland Laboratories Limited.NEULANDLABthis companyP/E ↑ premium | ₹18,376 Cr | 94.3x | 11.4x | 23.5% | 38.6x |
| AstraZeneca Pharma India Ltd.ASTRAZEN | ₹20,549 Cr | 88.9x | 25.7x | 22.8% | 86.6x |
| Onesource Specialty Pharma LimitedONESOURCE | ₹20,295 Cr | 76.8x | 3.4x | -98.0% | -92.4x |
| Eris Lifesciences LimitedERIS | ₹20,131 Cr | 71.4x | 7.3x | 11.9% | 45.5x |
| Sai Life Sciences LimitedSAILIFE | ₹19,113 Cr | 67.7x | 8.2x | 9.4% | 62.4x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Poly Medicure LtdPOLYMED | ₹17,352 Cr | 49.8x | 6.0x | 17.3% | 42.5x |
| Cohance Lifesciences LimitedCOHANCE | ₹17,161 Cr | 46.3x | 3.9x | 14.6% | 37.0x |
| JUBILANT PHARMOVA LIMITEDJUBLPHARMA | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
NEULANDLAB since 1 January, against earlier years.
Historical volatility
NEULANDLAB's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 16.0% |
| FY2022 | 15.0% |
| FY2023 | 23.0% |
| FY2024 | 30.0% |
| FY2025 | 22.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,477 Cr |
| Costs | |
| Interest | ₹8 Cr |
| Expenses | ₹1,147 Cr |
| Operating profitOperating Profit | ₹330 Cr |
| Other income and charges | |
| Profit before tax | ₹345 Cr |
| Tax | |
| Net profitNet Profit | ₹259 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,178 Cr |
| Equity capitalEquity Capital | ₹13 Cr |
| Reserves | ₹1,505 Cr |
| Borrowings | ₹157 Cr |
| Other liabilitiesOther Liabilities | ₹503 Cr |
| AssetsTotal Assets | ₹2,178 Cr |
| Fixed assetsFixed Assets | ₹955 Cr |
| Capital work in progressCWIP | ₹48 Cr |
| Investments | ₹109 Cr |
| Other assetsOther Assets | ₹1,066 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹317 Cr |
| Investing cash flowCash from Investing Activity | -₹298 Cr |
| Financing cash flowCash from Financing Activity | ₹25 Cr |
| Change in cashNet Cash Flow | ₹44 Cr |
Learn while you research
Academy chapters picked for Neuland Laboratories Limited. and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 94.3, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read